Life Sciences Portfolio (Select Companies)
-
Avidia
New protein structural motifs for treating human disease.
Acquired by Amgen (AMGN) -
Cabochon Aesthetics
A medical device company developing effective scientific solutions for aesthetic procedures.
Acquired by Ulthera -
Calithera Biosciences
A new class of anti-cancer therapeutics based on activation of caspases
(CALA) -
CardioThoracic Systems
Devices for minimally-invasive heart surgery
Acquired by Guidant (GDT) -
CareMedic
Revenue cycle management systems for hospitals
Acquired by Ingenix -
Catalyst Biosciences
Developer of engineered proteases as protein therapeutics that attack targets which cause disease.
PRIVATE -
Elcelyx Therapeutics
Elcelyx is a biotechnology company that is creating new therapeutics for the treatment of diabetes and obesity
-
FoldRx Pharmaceuticals
Treatments for diseases caused by misfolding of specific proteins
Acquired by Pfizer -
ForSight Labs
Ophthalmic incubator creating unique solutions that address unmet clinical needs in diseases of the eye.
PRIVATE -
ForSight Vision4
Developer of innovative drug delivery platform for ophthalmic use
Acquired by Roche
-
ForSight Vision5
Developing novel device solutions for ophthalmic diseases
Acquired by Allergan
-
Gliatech
Devices for the treatment of the nervous system
(GLIA) -
Holaira
Novel devices for treating lung diseases
-
IPC – The Hospitalist Company
Hospital-based physician practice management company
(IPCM) -
Miramar
Device for the treatment of hyperhidrosis and aesthetic complications of excessive sweating
PRIVATE -
Morphotek, Inc.
Next generation antibodies production technology.
Acquired by EISIA -
Mosaic Biosciences
Platform for tissue engineering using synthetic smart polymers
-
Moximed
An innovative treatment for patients with osteoarthritis
PRIVATE -
OncoMed Pharmaceuticals Inc.
Biological therapeutics targeting cancer stem cells
(OMED) -
Optiscan Biomedical Corporation
Instruments and sensors for accurate, automated measurement of blood glucose levels
PRIVATE -
Orexigen
Developer of drug treatments for obesity and related disorders.
(OREX) -
Perclose
Suture-mediated vascular closure systems
Acquired by Abbott Labs (ABT) -
Principia
Drug discovery company based on a proprietary chemistry platform that generates novel compounds with enhanced selectivity, high potency and longer duration of effect
-
Promedior Pharmaceuticals
Therapeutics to treat fibrosis
PRIVATE -
Ra Pharmaceuticals
Platform for orally available and cell permeable biologics
(RARX) -
Relievant Medsystems
Relievant Medsystems is developing a treatment for lower back pain
PRIVATE -
Replidyne
Drug discovery and development focused on a new class of antibiotics
(RDYN) -
Ribozyme Pharmaceuticals
RNA-based pharmaceuticals for human disease
(RZYM) -
Scioderm
Scioderm is focused on the development of innovative drugs for the treatment of chronic diseases of the skin.
Acquired by Amicus
-
Second Genome
Microbiome-based therapeutics for infection, inflammation, and metabolic disease
-
SetPoint Medical
Neuro-modulation platform for the treatment of a variety of acute and chronic diseases
PRIVATE -
SONIC Innovations
Digital hearing aids
(SNCI) -
Spine Wave, Inc.
Novel devices for spine surgery
PRIVATE -
Stemgent
Reagents for stem cell researchers
PRIVATE -
The Foundry
Medical device incubator
PRIVATE -
Thermage
Devices for cosmetic aesthetic surgery
(THRM) -
Third Millenium Healthcare Systems
Internet-based workflow solutions for healthcare organizations
Merged with CareMedic -
Threshold Pharmaceutical, Inc.
Developing targeted therapies for treatment of cancer.
(THLD) -
Tragara Pharmaceuticals
Developer of drugs for the treatment of cancer and inflammation-related diseases.
PRIVATE -
Transcend
Ophthalmic devices for diseases of the eye
PRIVATE -
Trellis Bioscience
Platform technology for monoclonal antibody development and production
PRIVATE -
Twelve
Developing a novel device for treatment of chronic cardiovascular diseases
PRIVATE -
Vapotherm
Vapotherm is developing high flow therapy for clinically effective respiratory support.
-
Vical
DNA-based pharmaceuticals for human disease
(VICL)